Tyra Biosciences, a clinical-stage biotech company specializing in precision medicines targeting FGFR biology, announced its participation in several upcoming investor conferences. These include the BofA Securities Health Care Conference on May 13, TD Cowen's Oncology Innovation Summit on May 26, and the Jefferies Global Healthcare Conference on June 3. The company will present updates on its drug pipeline, including its lead candidate dabogratinib and other investigational FGFR inhibitors for cancer and genetic conditions. Live webcasts will be available for investors to follow the presentations remotely.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
Western Star Resources has granted 2 million incentive stock options to its directors, officers, employees, and consultants. These options are exercisable until July 15, 2029, at a price of $0.30 per share. This move aligns with the company's goal to...
Ecopetrol, Colombia's largest energy company, will announce its financial and operating results for the second quarter of 2026 on August 3 after market close. A virtual conference will follow on August 4, featuring simultaneous Spanish and English br...
Galaxy Digital reports that large Bitcoin holders (whales) have not sold their holdings over fears of quantum computing risks. Instead, concerns about quantum threats seem to influence institutional investors who are hesitant to buy Bitcoin. Recent l...
